Cancer is the second leading cause of death in the US with metastatic disease remaining predominantly incurable. Year-over-year, new cancer cases and healthcare costs continue to increase. While precision medicine in the arena aims to select the most effective treatments for patients, existing approaches benefit only a minority of patients. Addressing this disconnect, Xilis is developing next generation MicroOrganoSphereTM technologies designed and intended to guide precision therapy for cancer patients and accelerate drug discovery. The firm is developing next generation technologies that provide a functional model of a patients individual tumor that can be directly tested for drug response - effectively enabling. clinicians to make timely treatment decisions for cancer patients and supporting drug development for world-leading pharmaceutical partners. The companys MicroOrganoSphereTM (MOS) technology and Precision Oncology Platform allow for rapid diagnostics, personalized patient care, and scalable patient-derived models for high-throughput drug discovery.
